Yair Feld

CorAssist Cardiovascular Ltd. develops therapeutic products for treating diastolic heart failure. Its proprietary technology enables the implantation of a device that directly improves cardiac diastolic function. The firm’s product, the ImCardia, is an elastic self-expanding device that is attached to the external left ventricular surface, through a simple off-pump closed heart procedure. The company was founded by Yair Feld, Yotam Reisner and Shay Dubi in 2003 and is headquartered in Haifa, Israel.

CorAssist Cardiovascular Ltd. develops therapeutic products for treating diastolic heart failure. Its proprietary technology enables the implantation of a device that directly improves cardiac diastolic function. The firm’s product, the ImCardia, is an elastic self-expanding device that is attached to the external left ventricular surface, through a simple off-pump closed heart procedure. The company was founded by Yair Feld, Yotam Reisner and Shay Dubi in 2003 and is headquartered in Haifa, Israel.

CorAssist Cardiovascular Ltd. develops therapeutic products for treating diastolic heart failure. Its proprietary technology enables the implantation of a device that directly improves cardiac diastolic function. The firm’s product, the ImCardia, is an elastic self-expanding device that is attached to the external left ventricular surface, through a simple off-pump closed heart procedure. The company was founded by Yair Feld, Yotam Reisner and Shay Dubi in 2003 and is headquartered in Haifa, Israel.

CorAssist Cardiovascular Ltd. develops therapeutic products for treating diastolic heart failure. Its proprietary technology enables the implantation of a device that directly improves cardiac diastolic function. The firm’s product, the ImCardia, is an elastic self-expanding device that is attached to the external left ventricular surface, through a simple off-pump closed heart procedure. The company was founded by Yair Feld, Yotam Reisner and Shay Dubi in 2003 and is headquartered in Haifa, Israel.

GeneGrafts Ltd. develops proprietary technology for modulating excitable tissues. Its technology is used for the treatment of cardiac arrhythmias, Parkinson's disease and other neurological disorders. The company was founded by Yair Feld, Lior Gepstein, Shimon Marom and Meira Melamed Frank in 2003 and is headquartered in Haifa, Israel.

GeneGrafts Ltd. develops proprietary technology for modulating excitable tissues. Its technology is used for the treatment of cardiac arrhythmias, Parkinson's disease and other neurological disorders. The company was founded by Yair Feld, Lior Gepstein, Shimon Marom and Meira Melamed Frank in 2003 and is headquartered in Haifa, Israel.

GeneGrafts Ltd. develops proprietary technology for modulating excitable tissues. Its technology is used for the treatment of cardiac arrhythmias, Parkinson's disease and other neurological disorders. The company was founded by Yair Feld, Lior Gepstein, Shimon Marom and Meira Melamed Frank in 2003 and is headquartered in Haifa, Israel.

CorAssist Cardiovascular Ltd. develops therapeutic products for treating diastolic heart failure. Its proprietary technology enables the implantation of a device that directly improves cardiac diastolic function. The firm’s product, the ImCardia, is an elastic self-expanding device that is attached to the external left ventricular surface, through a simple off-pump closed heart procedure. The company was founded by Yair Feld, Yotam Reisner and Shay Dubi in 2003 and is headquartered in Haifa, Israel.

GeneGrafts Ltd. develops proprietary technology for modulating excitable tissues. Its technology is used for the treatment of cardiac arrhythmias, Parkinson's disease and other neurological disorders. The company was founded by Yair Feld, Lior Gepstein, Shimon Marom and Meira Melamed Frank in 2003 and is headquartered in Haifa, Israel.